Janux Therapeutics, Inc.
JANX Healthcare Biotechnology
Janux Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $10.0 million, down 5.55% from fiscal 2024. In the quarter to June 2026, revenue grew 2,238.7%, EPS grew 36.4% and free cash flow grew 150.6%, each against the same quarter a year earlier.
Follow JANX
A Balance Sheet is a financial statement that provides a snapshot of a company's assets, liabilities, and shareholders' equity at a specific point in time. It follows the formula: Assets = Liabilities + Shareholders' Equity. Key components include current and non-current assets, current and long-term liabilities, and equity. The Balance Sheet helps businesses and investors evaluate financial stability, liquidity, and capital structure. It's essential for assessing the company's ability to meet its obligations and fund future operations.
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | |
|---|---|---|---|---|---|---|---|
Cash and Short Term Investments |
966.57 | 1,025.17 | 344.03 | 327.02 | 374.97 | 7.81 | 0.66 |
Receivables |
— | — | — | — | — | 8.00 | — |
Total current assets |
975.89 | 1,033.67 | 349.24 | 332.44 | 377.02 | 16.06 | 0.66 |
Property, Plant, Equpment (Net) |
3.85 | 4.86 | 7.00 | 7.09 | 1.41 | 0.16 | 0.02 |
Long-term assets (Other) |
3.42 | 3.70 | 3.33 | 2.21 | 1.21 | — | — |
Total non-current assets |
25.68 | 27.85 | 31.17 | 31.57 | 2.81 | 0.16 | 0.02 |
Total Assets |
1,001.57 | 1,061.52 | 380.41 | 364.01 | 379.82 | 16.22 | 0.68 |
Notes Payable |
— | — | — | — | — | — | 4.00 |
Accounts Payable |
4.97 | 4.03 | 2.42 | 2.16 | 2.46 | 0.43 | 0.27 |
Accrued Expenses |
17.63 | 11.68 | 7.39 | 8.18 | 3.78 | 0.75 | 0.36 |
Current Revenue (Deferred) |
— | — | 1.71 | 5.41 | 5.16 | 1.95 | — |
Other current liabilities |
— | — | — | — | 1.20 | 0.05 | 0.36 |
Total current liabilities |
25.00 | 17.46 | 13.03 | 16.51 | 12.80 | 3.18 | 4.63 |
Non-current Revenue (Deferred) |
— | — | — | 2.22 | 0.70 | 6.05 | — |
Total non-current liabilities |
19.75 | 21.28 | 23.03 | 26.76 | 0.70 | 6.05 | — |
Total liabilities |
44.74 | 38.74 | 36.06 | 43.27 | 13.50 | 9.23 | 4.63 |
Additional Paid In Capital |
1,303.83 | 1,258.32 | 512.40 | 432.70 | 413.97 | 0.10 | 0.01 |
Preferred Stock (Total) |
— | — | — | — | — | 21.62 | 4.00 |
Common Stock (Net) |
0.06 | 0.06 | 0.05 | 0.04 | 0.04 | 0.00 | 0.00 |
Retained Earnings |
(351.38) | (237.76) | (168.76) | (110.47) | (47.41) | (14.74) | (7.95) |
Common Equity (Total) |
956.82 | 1,022.78 | 344.35 | 320.74 | 366.33 | (14.64) | (7.94) |
Shareholders Equity (Total) |
956.82 | 1,022.78 | 344.35 | 320.74 | 366.33 | 6.99 | (3.95) |
Shareholders Equity and Liabilities (Total) |
1,001.57 | 1,061.52 | 380.41 | 364.01 | 379.82 | 16.22 | 0.68 |
Shares (Common) |
60.38 | 59.06 | 46.25 | 41.62 | 41.24 | 1.05 | 0.77 |
Shares (Preferred) |
— | — | — | — | — | 6.84 | 2.69 |
Shareholders Equity (Tangible) |
956.82 | 1,022.78 | 344.35 | 320.74 | 366.33 | 6.99 | (3.95) |
Net Debt |
(966.57) | (1,025.17) | (344.03) | (327.02) | (374.96) | (7.81) | (0.66) |
Total Debt |
— | — | — | 25.31 | 0.19 | 21.62 | 8.00 |